675 Safety and tolerability of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC)

Autor: Yiran Zhang, Kelly Curtis, Lanjia Lin, John Park, Douglas Adkins, A Dimitrios Colevas, Natalie Rainey, Bruno Fang, Minh Phan, Katie Kerrigan, Venessa Chin, Diogo Alpuim Costa, José Dinis, Siu-Chi Chang Sun, Michael Howland

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)

Externí odkaz: https://doaj.org/article/7aa15cf15277499fba361e2075238edb

CLO22-086: A Phase 2, Multi-Arm Study of Anti-CD47 Antibody Magrolimab in Combination With Docetaxel in Patients With Locally Advanced or Metastatic Solid Tumors

Autor: Vivek Subbiah, Ulka Vaishampayan, Sonam Puri, Lanjia Lin, Mark Chao, Giri Ramsingh, Shivaani Kummar, James F Strauss, Sandip P Patel

Publikováno v: Journal of the National Comprehensive Cancer Network. 20:CLO22-086

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::13d3be697523637a6c685ae26f7f0c0d
https://doi.org/10.6004/jnccn.2021.7172

Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer

Autor: Hope S. Rugo, Aditya Bardia, Frederik Marmé, Javier Cortes, Peter Schmid, Delphine Loirat, Olivier Tredan, Eva Ciruelos, Florence Dalenc, Patricia Gómez Pardo, Komal L. Jhaveri, Rosemary Delaney, Olivia Fu, Lanjia Lin, Wendy Verret, Sara M. Tolaney

Publikováno v: Journal of Clinical Oncology. 40:LBA1001-LBA1001

LBA1001 Background: HR+/HER2– disease is the most common subtype of metastatic breast cancer (MBC). Treatment includes sequential endocrine therapy combined with targeted agents followed by single-agent chemotherapy, with increasingly shorter durat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::85bc0d484d95500d30c8e27cf275927b
https://doi.org/10.1200/jco.2022.40.17_suppl.lba1001

aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis

Autor: Sharon J. Hutchinson, Thomas Berg, Jose Luis Calleja, William L. Irving, Vithika Suri, Longfeng Zhao, Junqi Niu, George V. Papatheodoridis, Philip J. Johnson, John F. Flaherty, Vana Sypsa, Jidong Jia, Peter C. Hayes, Ramazan Idilman, Zhengang Zhang, Rong Fan, Shuyuan Mo, Hidenori Toyoda, Lanjia Lin, Yabing Guo, Chaonan Zhu, Lei Shi, Hamish Innes, Pietro Lampertico, George N. Dalekos, Qing Xie, Takashi Kumada, Anuj Gaggar, Lai Wei, Maria Buti, Eleanor Barnes, Yongpeng Chen, Stephen T. Barclay, Xiaoguang Dou, Jinlin Hou, Satoshi Yasuda, Xiaoping Tang, Indra Neil Guha, Jian Sun, Harry L.A. Janssen, Yuanping Zhou, Jianqi Lian

Publikováno v: JOURNAL OF HEPATOLOGY
Fan, R, Papatheodoridis, G, Sun, J, Innes, H, Toyoda, H, Xie, Q, Mo, S, Sypsa, V, Guha, I N, Kumada, T, Niu, J, Dalekos, G, Yasuda, S, Barnes, E, Lian, J, Suri, V, Idilman, R, Barclay, S T, Dou, X, Berg, T, Hayes, P C, Flaherty, J F, Zhou, Y, Zhang, Z, Buti, M, Hutchinson, S J, Guo, Y, Calleja, J L, Lin, L, Zhao, L, Chen, Y, Janssen, H L A, Zhu, C, Shi, L, Tang, X, Gaggar, A, Wei, L, Jia, J, Irving, W L, Johnson, P J, Lampertico, P & Hou, J 2020, ' aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis ', Journal of Hepatology, vol. 73, no. 6, pp. 1368-1378 . https://doi.org/10.1016/j.jhep.2020.07.025

Background & Aims: Hepatocellular carcinoma (HCC) is the leading cause of death in patients with chronic hepatitis. In this international collaboration, we sought to develop a global universal HCC risk score to predict the HCC development for patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bba419081948e9032695ded8c4bfb709

Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care

Autor: Lindsey E Smith, Anu Osinusi, Richard Haubrich, Joel E. Gallant, Katherine K. Perez, Diana M. Brainard, Alex Soriano Viladomiu, Jihad Slim, Lijie Zhong, Anand P Chokkalingam, Robert L. Gottlieb, Nirav Shah, Alan S. Go, Robertino Mera-Giler, Jose I Bernardino, Helena Diaz-Cuervo, Holly Edgar, Tak Yin Owen Tsang, I-Heng Lee, Theresa L. Walunas, Philip A. Robinson, Chloé Phulpin, Shamim M Ali, Hao Hu, Susan Olender, Bindu Balani, Eboni G. Price-Haywood, B Nebiyou Bekele, BumSik Chin, Stéphane De Wit, Su Wang, Shobha Swaminathan, Lanjia Lin

Publikováno v: Clinical Infectious Diseases
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Background We compared the efficacy of the antiviral agent, remdesivir, versus standard-of-care treatment in adults with severe coronavirus disease 2019 (COVID-19) using data from a phase 3 remdesivir trial and a retrospective cohort of patients with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d8552ad50ba5b4036ca6ac52d686c4b